Chemical Component Summary | |
---|---|
Name | 3,7-DIMETHYL-1-(5-OXOHEXYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONE |
Identifiers | 3,7-dimethyl-1-(5-oxohexyl)purine-2,6-dione |
Formula | C13 H18 N4 O3 |
Molecular Weight | 278.31 |
Type | NON-POLYMER |
Isomeric SMILES | CC(=O)CCCCn1c(=O)n(C)c2ncn(C)c2c1=O |
InChI | InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3 |
InChIKey | BYPFEZZEUUWMEJ-UHFFFAOYSA-N |
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 38 |
Chiral Atom Count | 0 |
Chiral Atoms | n/a |
Bond Count | 39 |
Aromatic Bond Count | 10 |
Leaving Atoms | n/a |
Drug Info: DrugBank
DrugBank ID | DB00806 Different stereochemistry |
---|---|
Name | Pentoxifylline |
Groups |
|
Description | A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem] |
Synonyms |
|
Brand Names |
|
Affected Organism | Humans and other mammals |
Indication | For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs. |
Pharmacology | Pentoxifylline, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. |
Mechanism of action | Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist. |
Route of administration |
|
Categories |
|
ATC-Code | C04AD03 |
AHFS-Code | 20:24.00 |
CAS number | 6493-05-6 |
Drug Targets
Name | Sequence Search | Pharmacological Action | Actions |
---|---|---|---|
Adenosine receptor A2a | MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLNSNLQNVTNYFVVSLAA... | yes | antagonist |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B | MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNL... | yes | inhibitor |
cAMP-specific 3',5'-cyclic phosphodiesterase 4B | MKKSRSVMTVMADDNVKDYFECSLSKSYSSSSNTLGIDLWRGRRCCSGNL... | yes | inhibitor |
Adenosine receptor A1 | MPPSISAFQAAYIGIEVLIALVSVPGNVLVIWAVKVNQALRDATFCFIVS... | yes | antagonist |
5'-nucleotidase | MCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSK... | unknown | inhibitor |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682